Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.

ABSTRACT: Anti-angiogenic therapies target the tumor vasculature, impairing its development and growth. It was hypothesized over 40 years ago by the late Judah Folkman and Julie Denekamp that depriving a tumor of oxygen and nutrients, by targeting the tumor vasculature, could have therapeutic benefits. Identification of growth factors and signaling pathways important in angiogenesis subsequently led to the development of a series of anti-angiogenic agents that over the past decade have become part of the standard of care in several disease settings. Unfortunately not all patients respond to the currently available anti-angiogenic therapies while others become resistant to these agents following prolonged exposure. Identification of new pathways that may drive angiogenesis led to the development of s

SUBMITTER: Biel NM 

PROVIDER: S-EPMC4394020 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature